Xolair (omalizumab) / Roche, Novartis - LARVOL DELTA

A Case Series of Tofacitinib Treatment for Chronic Spontaneous Urticaria with Inadequate Response to Omalizumab. (PubMed, Clin Cosmet Investig Dermatol) - "Tofacitinib shows potential in treating CSU patients with inadequate response to omalizumab, offering significant early symptom improvement in some cases with manageable safety. Larger randomized controlled trials are needed for further validation."

Journal • Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Arthritis • Inflammatory Bowel Disease • Pruritus • Psoriatic Arthritis • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • Urticaria • Vitiligo

Dupilumab for Chronic Spontaneous Urticaria with Comorbid Type 2 Inflammatory Conditions: Case Report and Systematic Review of the Literature. (PubMed, Case Rep Dermatol) - "Chronic spontaneous urticaria (CSU) is a heterogeneous, Th2-driven condition where standard therapies, including antihistamines and omalizumab, are often insufficient. The majority achieved symptom control of urticaria as well as of the coexisting Th2 diseases, with only one report of mild side effects. Dupilumab is a suitable therapeutic option in patients with CSU and coexisting Th2-mediated conditions."

Journal • Asthma • Atopic Dermatitis • Chronic Spontaneous Urticaria • Dermatitis • Dermatology • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Immunology • Pulmonary Disease • Respiratory Diseases • Urticaria

Dual clinical remission in severe asthma and chronic rhinosinusitis with nasal polyps: a comparative review of biologic therapies. (PubMed, Expert Opin Biol Ther) - "We reviewed pivotal phase 3 and 4 trials (including SINUS-52, SYNAPSE, OSTRO, WAYPOINT, and the head-to-head EVEREST trial) evaluating dupilumab, mepolizumab, benralizumab, omalizumab, and tezepelumab. Emerging data from the WAYPOINT trial suggests tezepelumab (anti-TSLP) as a potent option for broad epithelial blockade. We advocate moving beyond isolated disease control toward a stratified 'United Airway' remission target guided by fractional exhaled nitric oxide, blood eosinophils, and immunoglobulin E levels."

Journal • Review • Asthma • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Nasal Polyps • Otorhinolaryngology • Pulmonary Disease • Respiratory Diseases • Sinusitis • IL5

Fab-Fc and Fab-Fab interactions of variable strength and valency contribute to the high concentration viscosity of IgG1 antibodies. (PubMed, Proc Natl Acad Sci U S A) - "This study suggests that a four-site self-interaction model, previously proposed for a single antibody (omalizumab), is broadly applicable to diverse IgG1. Beyond well-established variable domain engineering, this self-interaction model predicts that Fc engineering may reduce IgG1 viscosity, a much sought after goal to enable subcutaneous delivery. Clinically validated Fc mutations are demonstrated here to substantially reduce the viscosity for multiple IgG1 (-33 to -91% reduction, n = 6), supporting this emerging antibody design concept."

Journal

Challenges in Differentiating Chronic Inducible Urticaria from Chronic Spontaneous Urticaria. (PubMed, J Inflamm Res) - "Treatment is outlined according to current guidelines and evidence, noting that while second-generation H1-antihistamines are first-line for all CU patients, patients with CIndU often require trigger avoidance and occasionally off-label therapies (eg, omalizumab) for adequate control. In addition, this review discusses emerging treatments for CU, such as dupilumab, Bruton's tyrosine kinase (BTK) inhibitors, and barzolvolimab, which reflect the rapidly evolving therapeutic landscape. This review provides a practical guide for clinicians to differentiate and manage CSU and CIndU, by identifying key differences between CSU and CIndU based on current evidence."

Journal • Review • Cardiovascular • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

Real-World Comparison of Mepolizumab and Omalizumab in CRSwNP: Impact of Baseline Phenotypic Complexity (EAACI 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Immunology

Hereditary Alpha-Tryptasemia: a case series including Omalizumab treatment outcomes (EAACI 2026) - No abstract available

Clinical • Allergy • Immunology

Successful management with Omalizumab and high-dose venom immunotherapy in a patient with Kounis Syndrome and Clonal Mast Cell Activation Syndrome (EAACI 2026) - No abstract available

Clinical • Immunology

Complement C5 defines two immunological endotypes in CSU, with distinct autoantibody profiles and omalizumab responses: The INCA study (EAACI 2026) - No abstract available

Dermatitis • Immunology

Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child (EAACI 2026) - No abstract available

Clinical • Immunology

Efficacy of dupilumab vs omalizumab on symptom and quality of life burden in patients with severe chronic rhinosinusitis with nasal polyps and coexisting asthma: Results from the EVEREST study (EAACI 2026) - No abstract available

Clinical • HEOR • Allergy • Immunology

Clinically meaningful improvements in upper airway outcomes with dupilumab vs omalizumab by prior surgery status in severe chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST study) (EAACI 2026) - No abstract available

Clinical • Surgery • Immunology

Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project (EAACI 2026) - No abstract available

Clinical • Immunology

Dose-related efficacy of omalizumab in food-allergic children with severe asthma: OSAFA observational study (EAACI 2026) - No abstract available

Clinical • Observational data • Food Hypersensitivity • Immunology

Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset (EAACI 2026) - No abstract available

Clinical • Immunology

Predictors of response to omalizumab treatment in patients with chronic spontaneous urticaria: a post hoc analysis of a double-blind, randomized, phase 3 study (EAACI 2026) - No abstract available

Clinical • P3 data • Retrospective data • Immunology

Does Biological Therapy Modify NSAID Hypersensitivity? Experience with Omalizumab and Mepolizumab in Patients with Asthma and Nasal Polyps with N-ERD (EAACI 2026) - No abstract available

Clinical • Immunology

Prevalence and Types of Cancer in Patients Receiving Omalizumab: Insights from a Ten-Year Cohort (EAACI 2026) - No abstract available

Clinical • Allergy • Immunology

Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial (EAACI 2026) - No abstract available

Clinical • Immunology

Long-term effectiveness and safety of paediatric cow's milk oral immunotherapy in real life: outcomes with and without omalizumab support (EAACI 2026) - No abstract available

Clinical • Allergy • Food Hypersensitivity • Immunology

WAO Calls to Action regarding Omalizumab, Immunotherapy, and Ending First Generation Antihistamine Treatment (EAACI 2026) - No abstract available

Allergy • Food Hypersensitivity • Immunology

Efficacy of Omalizumab in Refractory Cholinergic Urticaria and Cholinergic Anaphylaxis: A Case Series (EAACI 2026) - No abstract available

Clinical • Immunology

Thyroid Autoantibody Seroconversion in Chronic Spontaneous Urticaria: Insights from Omalizumab Treated Patients (EAACI 2026) - No abstract available

Clinical • Immunology

Efficacy and Safety of Omalizumab Combined with Allergen-Specific Immunotherapy in the Treatment of Moderate-to-Severe Allergic Asthma: A Prospective Cohort Study in a Chinese Population (EAACI 2026) - No abstract available

Clinical • Immunology

Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria (EAACI 2026) - No abstract available

Clinical • Immunology